NCT02118415View on ClinicalTrials.gov

Targeted Natural Killer (NK) Cell Based Adoptive Immunotherapy for the Treatment of Patients With Non-Small Cell Lung Cancer (NSCLC) After Radiochemotherapy (RCT)

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

March 28, 2018

Study Completion Date

March 31, 2019

Conditions
NSCLC Stage IIIA/B
Interventions
OTHER

Hsp70-peptide TKD/IL-2 activated, autologous NK cells

Adjuvant treatment with Hsp70-peptide TKD/IL-2 activated, autologous NK cells following completion of standard radiochemotherapy (Cisplatin/Vinorelbine)

Trial Locations (1)

81675

Klinikum rechts der Isar, Strahlentherapie und Radiologische Onkologie, Munich

All Listed Sponsors
lead

Technical University of Munich

OTHER

NCT02118415 - Targeted Natural Killer (NK) Cell Based Adoptive Immunotherapy for the Treatment of Patients With Non-Small Cell Lung Cancer (NSCLC) After Radiochemotherapy (RCT) | Biotech Hunter | Biotech Hunter